However, we suggest that in MS patients, changes in the expression of AChE and BuChE would alter the availability of ACh and then this may lead to upregulation of ChAT and OCTN-1 expression in order to try to upload steady-state equilibrium of ACh levels. The gene discussed is SLC22A4; the disease is myeloid sarcoma.